Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
The U.S. FDA grants Santhera approval for AGAMREE® (vamorolone) as a therapeutic for Duchenne Muscular Dystrophy
Latest Hotspot
3 min read
The U.S. FDA grants Santhera approval for AGAMREE® (vamorolone) as a therapeutic for Duchenne Muscular Dystrophy
2 November 2023
Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.
Read →
Ciltacabtagene autoleucel Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Ciltacabtagene autoleucel Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Ciltacabtagene autoleucel, the Mechanism of Action for Ciltacabtagene autoleucel, and the drug target R&D trends for Ciltacabtagene autoleucel.
Read →
The commencement of Phase III SAR-bisPSMA by Clarity and PSI has been initiated
Latest Hotspot
3 min read
The commencement of Phase III SAR-bisPSMA by Clarity and PSI has been initiated
2 November 2023
Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.
Read →
 Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
Drug Insights
3 min read
Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.
Read →
The FDA gives IND approval for Biosyngen's BST02, the first global TIL treatment for liver cancer
Latest Hotspot
3 min read
The FDA gives IND approval for Biosyngen's BST02, the first global TIL treatment for liver cancer
2 November 2023
The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.
Read →
A Comprehensive Review of Clofarabine's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Clofarabine's R&D Innovations and Drug Target Mechanism
2 November 2023
This article summarized the latest R&D progress of Clofarabine, the Mechanism of Action for Clofarabine, and the drug target R&D trends for Clofarabine.
Read →
Deciphera announces positive top line results from pivotal Phase 3 trial of vimseltinib in treatment of Tenosynovial Giant Cell Tumors
Latest Hotspot
3 min read
Deciphera announces positive top line results from pivotal Phase 3 trial of vimseltinib in treatment of Tenosynovial Giant Cell Tumors
2 November 2023
Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).
Read →
Analysis on the Clinical Research Progress of ERK Inhibitor
Analysis on the Clinical Research Progress of ERK Inhibitor
2 November 2023
ERK, also known as Extracellular Signal-Regulated Kinase, is a crucial protein kinase that plays a significant role in various cellular processes within the human body.
Read →
The new indication for Sugemalimab has been approved in China, making it the world's first treatment for R/R ENKTL
Latest Hotspot
3 min read
The new indication for Sugemalimab has been approved in China, making it the world's first treatment for R/R ENKTL
2 November 2023
Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.
Read →
Pharmaceutical Insights: Cocaine Hydrochloride's R&D Progress
Drug Insights
4 min read
Pharmaceutical Insights: Cocaine Hydrochloride's R&D Progress
2 November 2023
This article summarized the latest R&D progress of Cocaine Hydrochloride, the mechanism of action for Cocaine Hydrochloride, and the drug target R&D trends for Cocaine Hydrochloride.
Read →
The novel Aβ-targeting drug Donanemab by Eli Lilly is applying for market authorization in China to treat Alzheimer's disease
Latest Hotspot
3 min read
The novel Aβ-targeting drug Donanemab by Eli Lilly is applying for market authorization in China to treat Alzheimer's disease
2 November 2023
Recently, the official website of the CDE shows that the marketing authorization application for Eli Lilly's new Alzheimer's medication, donanemab, has been accepted.
Read →
Advances in Clinical Research on D2 Receptor Antagonist
Advances in Clinical Research on D2 Receptor Antagonist
2 November 2023
The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.
Read →